Alpine Global Management’s Fortress Biotech FBIO Stock Holding History

Alpine Global Management’s Portfolio FBIO Stock Details FBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-1,481	Closed	-$57K	–	298
2019 Q4	$57K	Buy	+1,481	New	+$38K	0.01%	387
2015 Q2	–	Sell	-979	Closed	-$57K	–	1217
2015 Q1	$57K	Buy	+979	New	+$40.8K	0.02%	301

Other funds holding FBIO

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

CPWM LLC Seattle, Washington $1.06B AUM 14.49% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SAM

Shikiar Asset Management New York $396M AUM 41.06% 1-Year Est. Return

Alpine Global Management's FBIO Position: Q1 2020 in Review

Alpine Global Management sold out of Fortress Biotech (FBIO) in Q1 2020, closing a stake of 1,481 shares — an estimated $57K sold.

Alpine Global Management first reported a position in FBIO in Q1 2015 and held it in 2 quarters. The position peaked at $57K in Q4 2019. 55 funds tracked by Wall St. Rank hold FBIO as of Q1 2020.

Alpine Global Management reported no remaining Fortress Biotech position as of Q1 2020 after selling out during the quarter.
Alpine Global Management sold 1,481 Fortress Biotech shares in Q1 2020, an estimated $57K.
Alpine Global Management first reported a position in Fortress Biotech in Q1 2015 and held it in 2 quarters.
Alpine Global Management's Fortress Biotech position peaked at $57K in Q4 2019.
55 funds tracked by Wall St. Rank held Fortress Biotech as of Q1 2020.

Based on Alpine Global Management's 13F filing for Q1 2020, filed 9 Apr 2020.